<DOC>
	<DOCNO>NCT00653796</DOCNO>
	<brief_summary>This study design ass whether co-administration ezetimibe 10 mg atorvastatin 10 mg treatment na√Øve subject would effective treatment atorvastatin 10 mg alone reduce LDL-concentrations .</brief_summary>
	<brief_title>Ezetimibe Plus Atorvastatin Versus Atorvastatin Untreated Subjects With High Cholesterol ( P03434 )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Male nonpregnant female subject , demonstrate willingness participate comply procedure sign informed consent , &gt; =18 year &lt; =75 year age , eligible participate : baseline LDLC concentration &gt; =3.3 mmol/L ( 130 mg/dL ) &lt; =4.9 mmol/L ( 190 mg/dL ) ; baseline triglyceride concentration &lt; 3.99 mmol/L ( 350 mg/dL ) ; document history coronary heart disease ( CHD ) ; stable weight history 4 week prior baseline ; completion designate washout period prohibit medication ; fulfill exclusion criterion study . Body Mass Index &gt; =30 kg/m^2 baseline ( increase 35 kg/m^2 protocol amendment 1 Liver transaminase ( ALT , AST ) &gt; 1.5 time upper limit normal active liver disease baseline Evidence current myopathy ( exclude subject CK &gt; 1.5 time upper limit normal baseline Clinical lab test ( CBC , blood chemistry , urinalysis ) result outside normal range unacceptable investigator baseline Type II diabetes mellitus poorly control ( HbA1c &gt; 9 % ) , newly diagnose , change antidiabetic therapy within 3 month baseline Type I diabetes mellitus stable insulin regimen 3 month prior baseline recent history repeat hypoglycaemia unstable glycaemic control Known hypersensitivity HMGCoA reductase inhibitor Alcohol consumption &gt; 14 unit ( woman ) /21 unit ( men ) ( unit = 0.5 pint beer wine , single measure spirit ) Pregnancy , lactation , condition situation , opinion investigator , pose risk subject interfere participation study . Any following medical condition : HIV positive ; congestive heart failure define NYHA Class III IV ; uncontrolled cardiac arrhythmia ; MI , acute coronary insufficiency , CABG , angioplasty within 3 month baseline ; unstable severe peripheral artery disease within 3 month baseline ; newly diagnose unstable angina pectoris baseline ; uncontrolled hypertension systolic blood pressure &gt; 100 mm Hg baseline ; uncontrolled endocrine metabolic disease know influence serum lipid lipoproteins ; impaired renal function nephritic syndrome baseline ; disorder hematological , gastrointestinal , central nervous system ; diseases hyperlipidaemia coronary heart disease would interfere study evaluation ; cancer . Drug abuse emotional intellectual problem ; Use certain drug , food , agent know alter cholesterol level cause pharmacokinetic interaction either ezetimibe atorvastatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>